Newsfile Corp
26 Jul 2026, 16:55 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail's NHS-Galleri Trial failed to observe a statistically significant reduction in Stage III-IV cancers. — Failure to meet the primary endpoint of a flagship clinical trial directly undermines the company's core value proposition and product efficacy.
-0.90Grail is facing a class action lawsuit alleging it misled investors regarding the probability of the NHS-Galleri trial's success. — Securities litigation creates significant legal overhang, potential financial liabilities, and damages management credibility.
-0.50Grail's stock price fell more than 50% following the announcement of the trial's failure on February 19, 2026. — While the price drop has already occurred, it establishes a baseline of severe investor devaluation and high volatility.
-0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a class action lawsuit alleging securities fraud and a 50% stock price drop following failed trial endpoints.
The company is mentioned in the context of an investor class action lawsuit for substantial losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
2h ago
